Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-4198 + Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT07867262Phase 1Not yet recruiting
- Sponsor
- Genentech
- Start
- Dec 2026
- Primary completion
- Aug 2030
01
Overview
Phase 1, open-label trial of GDC-4198 in breast cancer (3 arms), sponsored by Genentech. Primary endpoint: Incidence and Severity of Adverse Events at 30 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
GDC-4198
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07867262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867262.